How long must dying patients wait for justice? In a recent edition of the Wall Street Journal, Gregory Conko, Director of Food Safety Policy at the Competitive Enterprise Institute, an advocacy group based in Washington DC, [...]
Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York have found a rare mutation in some GIST tumors. In a series of 61 patients with wild-type GIST, they found that three of them (5%) had mutations in a gene called BRAF. This same mutation, a “V600E” mutation in exon 15 of the BRAF gene, occurs frequently in melanoma. They also found the same mutation in one of 28 GIST patients that were resistant to Gleevec.
Here is a video for the Livestrong.com Guru Challenge - "Dare To" Contest. Watch the video and help fight GIST.
Gleevec receives FDA priority review as first therapy to reduce recurrence of GI stromal tumors after surgery East Hanover, August 27, 2008 — Novartis announced today that Gleevec® (imatinib mesylate) tablets has been granted priority [...]
Jodi Merry wrote this editorial about GIST Cancer titled When is Enough Enough?